Article
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.
Journal of viral hepatitis - 1 Nov 2017
Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay J-P, Vanwolleghem T, Verlinden W, Brixco C, Decaestecker J, de Galocsy C, Janssens F, Van Overbeke L, Van Steenkiste C, D'Heygere F, Cool M, Wuyckens K, Nevens F, Robaeys G
Abstract excerpt
Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.